Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24418746 | 0.81 | TDP1 (0.41) | MEN1KMT2ATDP1 | |
| SCHEMBL5735758 | 0.79 | MEN1 (0.33) | MEN1KMT2ATDP1 | |
| SCHEMBL29316573 | 0.78 | CES2 (0.33) | MEN1KMT2ATDP1 | |
| SCHEMBL25062278 | 0.77 | MEN1 (0.33) | MEN1KMT2ATDP1 | |
| SCHEMBL30574208 | 0.77 | ALDH1A1 (0.43) | MEN1KMT2ATDP1 | |
| SCHEMBL9447837 | 0.76 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL8958557 | 0.76 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL18173574 | 0.76 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL8958401 | 0.76 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL8958237 | 0.76 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4284446-A2 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4243935-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Janssen Biotech, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023144723-A1 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023084397-A1 | MACROCYCLIC COMPOUNDS AND DIAGNOSTIC USES THEREOF | JANSSEN BIOTECH, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2022101771-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220143231-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11236103-B2 | Bifunctional compounds | BIOTHERYX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3830093-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | Biotheryx, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020023782-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | BIOTHERYX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143231-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | MEN1 314/4885KMT2A 1805/4885SMN1; SMN2 264/4885 |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | MEN1 3334/4885KMT2A 1110/4885SMN1; SMN2 682/4885 |
| US-11236103-B2 | Bifunctional compounds | CDK2, CDK6, CDK5 | MEN1 3334/4885KMT2A 1110/4885SMN1; SMN2 682/4885 |
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | MEN1 314/4885KMT2A 1805/4885SMN1; SMN2 264/4885 |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | MEN1 3334/4885KMT2A 1110/4885SMN1; SMN2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.